<![CDATA[HARMONi-6: Evaluating the Safety and Generalizability of Ivonescimab in NSCLC]]>

Data ReadoutivonescimabNeutral

AI Analysis

Summary

Dr. Sivraj Muralikrishnan presented HARMONi-6 safety analysis for ivonescimab in NSCLC, focusing on VEGF-related toxicities and global generalizability of the treatment.

Clinical Trial Data

Outcome Details

Safety findings analysis for HARMONi-6 trial addressing VEGF-related toxicities

Importance:3/10

Sentiment:

0.00

NSCLCSafetyIvonescimabHARMONi-6VEGF toxicityGeneralizability

Related Companies

$GBCYD

Read the original article

Published by Cancer Network on July 9, 2026 12:00 PM

Read Original